ArticleCancer immunology, immunotherapy : CII2024

Immunotherapy may be more appropriate for ERBB2 low-expressing extramammary paget's disease patients: a prognosis analysis and exploration of targeted therapy and immunotherapy of extramammary paget's disease patients.

Jiawen Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.